The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway plays an important role in cell survival and the development of cancer. Macrophage migration inhibitory factor (MIF) is a critical inflammatory cytokine that was recently associated with tumorigenesis and that potently inhibits apoptosis. This may involve inhibition of p53-dependent genes, but the initiating molecular mechanism of how MIF controls survival/apoptosis is unknown. Here, we show that MIF prevents apoptosis and promotes tumor cell survival by directly activating the Akt pathway. MIF enhanced Akt activity in primary and immortalized fibroblasts (MEF and NIH/3T3), HeLa cervix carcinoma cells and various breast cancer cell lines. Activation was abolished by kinase inhibitors Ly294002 and PP2 and in Src/Yes/Fyn(SYF) À/À and CD74
À/À (MEFs), while being enhanced in CD74-overexpressing MEFs, demonstrating that the MIF-induced Akt pathway encompasses signaling through the MIF receptor CD74 and the upstream kinases Src and PI3K. Akt was activated by exogenous rMIF and autocrine MIF action, as revealed by experiments in MIF À/À MEFs and antibody blockade. siRNA knockdown of CSN5/JAB1, a tumor marker and MIF-binding protein, showed that JAB1 controls autocrine MIF-mediated Akt signaling by inhibition of MIF secretion. Akt activation by MIF led to phosphorylation of the proapoptotic proteins BAD and Foxo3a. Apoptosis inhibition by MIF was functionally associated with Akt activation as it was abolished by overexpression of the Akt pathway inhibitor PTEN and occurred independently of p53. This was shown by studying DNA damage-induced apoptosis in fibroblasts, the Fas death pathway in HeLa cells that do not express functional p53, and etoposide-induced apoptosis in breast carcinoma cells expressing mutant p53. Importantly, dependence of breast cancer cell survival on MIF correlated with Akt activation and the PTEN status of these cells. Thus, MIF can directly promote cell survival through activation of the PI3K/Akt pathway and this effect is critical for tumor cell survival.
Introduction
The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway plays an important role in the cellular response to growth factors and regulates key cellular functions such as growth, metabolism, migration, apoptosis and survival (Song et al., 2005) . PI3K/Akt signaling is initiated by activation of receptor tyrosine kinases or G protein-coupled receptors (Wetzker and Bohmer, 2003) . Activation involves PI3K recruitment to the receptor involving PI3K's Src homology domains and/or Src-type kinase action. PI3Ks are lipid kinases, which catalyze the generation of phosphatidylinositol-3,4,5-triphosphate (PIP3), the levels of which are controlled by the lipid phosphatase and tumor suppressor phosphatase and tensin homolog (PTEN) (Koyasu, 2003) . PIP3 recruits the Ser-/Thr-kinase Akt to the membrane and recruitment of Akt leads to its activation through phosphorylation on Thr308 and Ser473 by membrane-associated kinases PDK-1 and PDK-2, respectively (Alessi and Cohen, 1998; Brazil et al., 2002; Song et al., 2005) .
Activation of PI3K/Akt leads to various cellular responses, but most importantly, Akt activation provides cells with a crucial survival signal allowing them to withstand apoptosis. The prosurvival and antiapoptotic function of Akt is mediated by phosphorylation of target proteins including the proapoptotic Bcl-2 family member protein BAD. Upon phosphorylation by Akt, BAD can no longer inhibit the antiapoptotic function of Bcl-2 or Bcl-xL on the mitochondrial apoptosis pathway, promoting cell survival (Datta et al., 2002) . Powerful survival control by Akt is also achieved through inhibition of Foxo transcription factors, preventing Foxo-mediated transcriptional activation of Fas ligand or TRAIL (Song et al., 2005) . The major function of glycogen synthase kinase-3 (GSK-3b) is the control of glucose utilization upon insulin stimulation. PhosphoAkt inactivates GSK-3b, which promotes glucose utilization. Phosphorylation of GSK-3b by Akt and stimulation of glucose metabolism prevents activation of the proapoptotic Bax protein by conformational change and promotes growth factor-independent survival (Song et al., 2005) .
Thus, Akt activation leads to the regulation of critical cellular targets toward antiapoptotic functions. PI3K/ Akt signaling thus plays a major role in oncogenesis and it is not surprising that deregulations of components within this pathway are targets for cancer treatment (Chang et al., 2003; Osaki et al., 2004; Hennessy et al., 2005) .
Macrophage migration inhibitory factor (MIF) is a conserved 12.5 kDa mediator that functionally belongs to the class of inflammatory cytokines, but has unique structural properties (Sun et al., 1996) . MIF is secreted by immune and parenchymal cells upon inflammatory and stress stimulation, but is also expressed intracellularly in various cells, where it likely serves regulatory functions, that are mediated by protein-protein interactions (Calandra and Roger, 2003) . MIF plays a pivotal role in the pathogenesis of acute and chronic inflammatory diseases including septic shock, rheumatoid arthritis and atherosclerosis (Bernhagen et al., 1993; Calandra and Roger, 2003; Morand et al., 2006) .
Moreover, MIF has been implicated in cancerogenesis and to constitute a link between chronic inflammation and cancer. MIF levels are markedly elevated in numerous tumors such as prostate tumors, breast cancer, melanomas, colon carcinomas and gliomas. MIF promotes cell proliferation and blockade of MIF by antibodies or genetic deletion leads to reduced cellular proliferation and inhibition of tumor growth and angiogenesis (Takahashi et al., 1998; Chesney et al., 1999; Hudson et al., 1999; Shimizu et al., 1999; Mitchell and Bucala, 2000; Bando et al., 2002; Amin et al., 2003; Nishihira et al., 2003) . These effects may involve MIF-mediated regulation of CD74-dependent ERK mitogen-activated protein kinase (MAPK) signaling and activation of cytosolic phospholipase A2 (cPLA2) (Mitchell et al., 1999; Leng et al., 2003; Lue et al., 2006) , modulation of activities of the tumor-associated protein c-Jun activation domain-binding protein-1 (JAB1) and signaling through the COP9 signalosome (CSN) (Kleemann et al., 2000; Burger-Kentischer et al., 2005) . JAB1 is CSN5 of the CSN and functions as coactivator of activator protein-1 (AP-1)-driven gene expression and participates in CSN-mediated activation of SCF-E3 ligase-dependent proteasomal degradation of cell cycle regulators such as p27 or p53 (Chamovitz and Segal, 2001 ; Bech-Otschir et al., 2002; Wolf et al., 2003) . MIF inhibits p53-dependent gene expression and suppresses apoptosis associated with p53 activation and redox stress (Hudson et al., 1999; Mitchell et al., 2002; Fingerle-Rowson et al., 2003; Nguyen et al., 2003) .
However, the upstream molecular mechanism through which MIF initiates its prosurvival, antiapoptotic and protumorigenic effects and that could connect it with p53-dependent apoptotic processes is unknown. As the PI3K/Akt pathway is pivotal in controlling cell survival and apoptosis, we investigated whether MIF could directly activate Akt signaling and participate in Akt-mediated survival control, and whether such an effect could causally connect to MIF's antiapoptotic activity.
Results

Phosphorylation and activation of Akt by MIF and dependence on PI3K, Src kinase and CD74
We demonstrated previously that MIF leads to a rapid activation of MAPK signaling in fibroblasts and macrophages (Lue et al., 2006) . In an extension of these studies, we noticed that MIF-mediated phosphorylation of ERK1/2 was not only ablated by MAPK inhibitors, but also by the PI3K inhibitors Ly294002 and wortmannin ( Figure 1a ). This could mean that exogenous rMIF directly stimulates PI3K/Akt signaling. Recent data have indicated that MIF can regulate angiogenesisrelated signaling in endothelial cell migration through a mechanism involving PI3K (Amin et al., 2003 (Amin et al., , 2005 .
We thus investigated whether the antiapoptotic activities of MIF could be owing to a direct upregulation of the Akt signaling pathway. NIH/3T3 fibroblasts were treated with exogenous rMIF and Akt phosphorylation evaluated over 6 h. rMIF led to a marked enhancement of endogenous Akt phosphorylation, with a three-to sixfold stimulation observed at 10-60 min ( Figure 1b) and at a concentration of 50-100 ng/ml rMIF ( Figure 1c) . Moreover, MIF also markedly stimulated Akt activity; when immunoprecipitated from fibroblast lysates, MIF-stimulated phospho-Akt, phosphorylated GSK-3b in an in vitro kinase assay (Figure 1c ). This suggested that rMIF, at pathophysiologically relevant concentrations, leads to a rapid and marked activation of Akt, an effect unlikely to involve intermediate MIF-mediated growth factor secretion.
To investigate whether Akt activation by MIF was dependent on PI3K, we applied a chemical PI3K inhibitor. Ly294002 completely suppressed the phosphorylation of Akt induced by MIF (Figure 1d ). Also, MIF-induced Akt activation was reduced in fibroblasts overexpressing dominant-negative PI3K (data not shown), confirming dependence on PI3K activation.
As Src-type kinases are upstream mediators of Akt signaling and as MIF has been shown to activate Src kinases (Lue et al., 2006) , we tested whether rMIFstimulated Akt activation was dependent on tyrosine kinase activity, in particular Src-family kinase activity. First, the effect of the broad-spectrum tyrosine kinase inhibitor genistein was evaluated. Genistein markedly downregulated MIF-induced Akt phosphorylation in fibroblasts (Figure 2a) . Likewise, the Src kinase inhibitor PP2 strongly inhibited MIF-induced phospho-Akt, suggesting involvement of a Src kinase (Figure 2a ). To confirm this notion, Src-kinase-deficient mouse embryonic fibroblasts (MEFs) with the Src-, Yes-and Fynkinases genetically deleted, were applied (Figure 2b Figure 2b and c). In fact, as stable transfection led to an overexpression of Src compared to wild-type cells, the MIF-triggered Akt phosphorylation was also higher than in the wtMEFs.
CD74 functions as a membrane receptor for MIF and has been implicated in MIF-mediated MAPK signaling. We therefore asked whether MIF-induced Akt activation was mediated by CD74. When treated with rMIF, control MEFs expressing appreciable concentrations of surface CD74 exhibited a strongly enhanced Akt phosphorylation rate (up to eightfold) between 5 and 60 min (Figure 3a) . In contrast, CD74
MEFs showed no such Akt phosphorylation peak following MIF treatment. Interestingly, however, the CD74 À/À MEFs showed some residual Akt phosphorylation activity, which occurred between 30 and 120 min after rMIF addition and which appeared to be due to decreasing overall Akt levels at these time intervals. To substantiate further that MIF-stimulated Akt phosphorylation involves a CD74-driven pathway, the CD74 À/À MEFs were transfected to express CD74 transiently. In fact, restoration of CD74 led to a recovery of MIF-induced Akt phosphorylation between 5 and 60 min (Figure 3b ). Together, these data indicate that Akt activation is initiated by interaction of MIF with its membrane receptor CD74 and characterize the upstream signaling processes necessary for MIF-induced Akt activation as consisting of a CD74/Src-type kinase/PI3K pathway.
Activation of PI3K/Akt signaling by an autocrine MIF route MIF's role in tumorigenesis has been suggested to involve autocrine MIF activity. In fact, MIF is prestored intracellularly and released upon stimulation, but also continuously by cycling tumor cells (Bernhagen et al., 1993; Mitchell and Bucala, 2000; Flieger et al., 2003) . Activation of sustained ERK signaling is mediated by autocrine MIF action (Mitchell et al., 1999) . We thus considered that Akt activation can be activated by an autocrine MIF loop.
Akt activity from cultured MIF
MEFs was compared with that from corresponding wtMEFs. wtMEFs exhibited >twofold higher Akt activity levels than MIF À/À MEFs ( Figure 4a ). This implied that endogenous MIF was secreted to induce Akt by an autocrine route, which was thus analysed in more detail. ELISA analysis of MIF in the supernatants of cultured wtMEFs showed that maximal constitutive MIF secretion was measurable 4-8 h after medium change (3.3-6.3 ng/ml produced by a 200 000 cell culture), with secretion plateauing thereafter. As rMIF is somewhat less potent than endogenously produced MIF (Bernhagen et al., 1993) , this concentration roughly corresponds to the optimum of the rMIF dose-response curve (50 ng/ml). In fact, a 20 min incubation with media from 4 h cultures of wtMEFs triggered Akt activation similar to 50 ng/ml activate Akt signaling in an autocrine manner, whereas MIF is also able to rapidly 'de novo' activate this pathway.
Role for JAB1 in MIF secretion and autocrine MIFmediated Akt signaling Intracellular MIF is a store for MIF secretion via the unconventional export pathway (Bernhagen et al., 1993; Flieger et al., 2003) and interacts with JAB1 (Kleemann et al., 2000) . We investigated the possibility that JAB1 could act as a regulator of MIF secretion to control Akt signaling by interference with the autocrine MIF loop. HEK293 cells were subjected to JAB1-siRNA knock down and endogenous phospho-Akt in these cultures was compared with that in controls transfected with scrambled RNA. Notably, phospho-Akt was increased in JAB1 siRNA-treated cells by B3-fold ( Figure 5a ). As JAB1 has not been reported to be involved in regulating Akt, we hypothesized that JAB1 might participate in regulating MIF secretion to indirectly influence Akt. In fact, ELISA analysis of MIF in the supernatants showed that MIF increased >4-fold, when JAB1 was knocked down (Figure 5b ). Compared to the marked relative increase in MIF in the culture supernatants, the cellular levels of MIF were only marginally lower in the JAB1 siRNA-treated cells (Figure 5c ). This latter notion was confirmed by comparing JAB1 þ /À heterozygous MEFs with corresponding JAB1
þ / þ MEFs (data not shown). In fact, as MIF is constitutively expressed in HEK293 cells at fairly high levels (Kleemann et al., 2000) , the large increase in secreted MIF in the JAB1 siRNA-treated cells would not be expected to be paralleled by appreciable changes in cellular MIF. Thus, the JAB1-MIF interaction apparently serves to sequester MIF in the cytosol and to inhibit its secretion, resulting in reduced autocrine MIFmediated Akt signaling.
Direct link between MIF-mediated Akt signaling and cell survival/apoptosis Among the functions regulated by PI3K/Akt, control of cell survival is most important and involves a switchingoff of the mitochondrial apoptosis pathway.
As MIF has previously been suggested to suppress apoptosis, we asked whether activation of PI3K/Akt by MIF was directly linked to apoptosis inhibition. The experiments in Figures 1 and 4 were in support of the notion that MIF enhances cell survival in an Aktmediated manner, because MIF upregulated phosphorylation of GSK-3b by Akt. Akt-dependent GSK-3b phosphorylation results in improving cell survival via enhanced glucose utilization and derepression of cyclin D1. However, the Akt/GSK-3 pathway is not the main route through which Akt secures survival and our GSK3b experiments were performed in vitro.
Therefore, we investigated the effect of MIF-mediated Akt activation on two key Akt survival substrates in vivo. We first studied the phosphorylation of BAD. NIH/3T3 fibroblasts, ectopically overexpressing BAD, were incubated with rMIF. This led to a >4-fold increase in the phosphorylation of BAD at its Akt site (Figure 6a ). Furthermore, MIF upregulated the phosphorylation of Foxo3a at an Akt-specific site (B2-fold; Figure 6b ). These findings strongly indicated that MIF directly promotes fibroblast survival through Akt.
To confirm this notion by functional apoptosis/ survival analyses, we studied whether Akt activation by MIF was directly linked to enhanced cell survival. NIH/3T3 fibroblasts were treated with the topoisomerase inhibitor camptothecin to trigger DNA damagemediated apoptosis and apoptosis in the presence versus absence of rMIF was analysed and aligned with rMIF-induced Akt activation. Akt activation by rMIF at 20 min ( Figure 7a ) was directly associated with a B50% enhancement of survival, being statistically significant 4-8 h after the apoptotic stimulus (Po0.005; Figure 7b and c).
This functional link was confirmed in a HeLa cell system of Fas-mediated apoptosis and endogenous MIF induction. HeLa cells expressing MIF under the control of a Tet-off cassette were transfected with Fas receptor and MIF was induced by doxycyclin removal. Confirming earlier results, MIF was induced two-to three-fold by doxycyclin removal ( (Nguyen et al., 2003) and Supplementary Figure 2 ), an effect maintained for at least 4 h after apoptosis induction. Phospho-Akt increased between 1 and 8 h after MIF induction and addition of Fas agonist, peaking at 60 min and this increase was associated with a decrease in the number of apoptotic cells observed between 1 and 18 h (B4-fold) (Figure 7d and e). HeLa cells are cervix carcinoma cells expressing minute concentrations of p53, which in addition is functionally inactivated by the HPV-E6 protein, thus representing p53-null cells. Therefore, Akt-dependent suppression by MIF of Fas-induced apoptosis in HeLas occurs in a p53-independent manner. A direct link between autocrine MIF-mediated Akt activation and survival was underpinned in MEFs treated with tertbutylhydroperoxide to induce reactive oxygen species (ROS)-induced apoptosis. Compared with MIF À/ À MEFs, wtMEFs were protected from apoptosis by a factor of B3 (Po0.005) and this effect was associated with a B3-fold increase in phospho-Akt (Supplementary Figure 3 ), corroborating the role for autocrine MIF in Akt activation and survival.
To establish unanimously a functional role for the PI3K/Akt pathway in MIF-mediated apoptosis inhibition, MIF-Tet-off-HeLa cells were transfected with PTEN-siRNA to knock down the major PI3K antagonist PTEN (knock down: B70-80%), leading to a functional increase in Akt signaling. Apoptosis was evaluated 4 h after induction with Fas ligand and compared with that survival (Figure 7f ). Thus, when the Akt pathway in HeLa cells was strongly activated through depletion of its endogenous counter-regulator PTEN, MIF was unable to increase HeLa cell survival any further. Inversely overexpression of PTEN (B3-fold overexpression compared to control) led to a potent blockade of the Akt survival pathway and an increase in the apoptosis rate to around 80%. Of note under these conditions, MIF was unable to improve survival (Figure 7f and Supplementary Figure 4 ). In addition, the survival effect of MIF was evaluated in the presence of Ly294002 as an alternative means to block PI3K/Akt signaling. When the HeLa cells were treated with dimethylsulfoxide (DMSO) control solution, MIF was able to strongly suppress apoptosis of the cells, whereas the pro-survival effect of MIF was greatly diminished in the presence of Ly294002 (2.5 versus 37% apoptotic cells; n ¼ 2 experiments). Thus, interfering with the Akt pathway by increasing PTEN or adding Ly294002, ablated the survival effects of MIF, further demonstrating a functional link between MIF's effect on the Akt pathway and its role in the regulation of apoptosis and cell survival.
Role for MIF-mediated Akt activation in breast cancer cell survival
To investigate more extensively whether PI3K/Akt activation by MIF was linked to its prosurvival role in cancer cells, three breast cancer cell lines with different PTEN and phospho-Akt expression features were analysed in comparison with normal mammary cells. The phospho-Akt/Akt ratio was analysed in the context of MIF expression levels, responsiveness to rMIF and JAB1 levels. Furthermore, endogenous MIF secreted by the breast cancer cells was blocked with a MIF mAb and the effect of MIF blockade on the apoptotic response of these cells was compared with that of the PI3K inhibitor Ly294002. As predicted (Perren et al., 1999; DeGraffenried et al., 2004) , MDA-MB-468 breast cancer cells were null for PTEN, ZR-75-1 cells only expressed minute levels of PTEN, which is functionally inactivated, ZR-75-1 cells are hemizygous PTEN þ /À breast cancer cells representing an infiltrating ductal carcinoma. The remaining allele carries a missense mutation, such that ZR-75-1 cells express weak levels of a functionally inactivated PTEN protein, therefore essentially behaving as PTENnull cells, and MCF-7 cells showed strong PTEN expression. MCF-12A cells, representing a model of normal mammary epithelial cells, expressed appreciable concentrations of the PTEN protein (Figure 8a ). Accordingly, MDA-MB-468 and ZR-75-1 cells exhibited very high Akt phosphorylation ratios, whereas phosphoAkt was weak in MCF-7 and MCF-12A cells. All cell types expressed MIF, confirming constitutive intracellular expression of this mediator in many epithelial cells (Calandra and Roger, 2003) . ZR-75-1 and MCF-7 cells showed strong MIF expression that was markedly higher than that in MDA-MB-468 and MCF-12A cells ( Figure  8a and b) . High MIF expression correlated with a high Akt phosphorylation ratio in ZR-75-1 but not MDA-MB-468 and MCF-7. As expected, transient addition of exogenous rMIF for 20 min led to a significant increase in Akt phosphorylation (B2-fold) in the normal mammary epithelial cells. Among the breast cancer cells, exogenous rMIF led to a further increase in phosphoAkt (by B35%) only in MDA-MB-468, as these expressed low endogenous MIF. Although the P-Akt/ Akt ratio was relatively low in MCF-7 (because of high PTEN), rMIF did not influence Akt phosphorylation. This was likely due to high endogenous MIF in these cells. Also, there was no rMIF effect on ZR-75-1, as these cells exhibited both high P-Akt/Akt and endogenous MIF. Thus, breast cancer cells are unresponsive to exogenous rMIF when the Akt pathway is already maximally activated ('low PTEN') and when cancer cells express high endogenous MIF. Similarly, Akt activation in breast cancer cells cannot be modulated by exogenous MIF when the PI3K/Akt pathway is functionally blocked ('high PTEN'). Intriguingly, however, upregulation of Akt signaling in MDA-MB-468 suggests that exogenous MIF can contribute to Akt activation under 'low PTEN conditions', when the cells do not at the same time express high levels of endogenous MIF. JAB1 levels did not apparently correlate with the P-Akt/Akt ratio.
To ask whether Akt activation by MIF in breast cancer cells under the various PTEN states was functionally connected with cancer cell survival, the apoptotic response of these cells to etoposide was measured in the presence versus absence of autocrine MIF action and survival compared to Ly294002 blockade experiments. Following apoptosis induction, survival of non-cancer MCF-12A cells strongly depended on autocrine MIF signaling, as a neutralizing MIF mAb led to a dramatic increase in apoptosis rate from B10 to 60% (Figure 8c and Supplementary Figure  5 ). This effect was even stronger than survival inhibition by 5 mM Ly294002, a concentration that is threefold above the IC 50 value (IC 50 ¼ 1.6 mM) of this inhibitor. Corresponding to the results in Figure 8a and b, blockade of autocrine MIF action in the cancer cells led to the strongest loss in survival rate in MDA-MB-468, where the effect of anti-MIF was stronger than that induced by 1 mM Ly294002. In contrast, when PTEN was high (MCF-7) or a cancer cell combining a PTENnull phenotype with very high endogenous MIF was analysed (ZR-75-1), the apoptosis-enhancing effect of anti-MIF was equally or less potent than that obtained by 1 mM Ly294002. The MIF blockade experiments showed that MIF contributed to breast cancer cell survival, especially when cells featured a PTEN-null phenotype. In summary, at conditions under which MIF is able to regulate activation of the Akt survival pathway in breast cancer cells, it is functionally involved in the survival of these cells.
Discussion
We provide evidence that the inflammatory cytokine MIF is a critical promoter of cell survival both in fibroblasts as well as in cervix carcinoma and breast cancer cells and that this function is predominantly due to a rapid triggering of the Akt pathway by either exogenous addition of MIF -representing paracrine or circulating MIF action -or by autocrine MIF activity of the cancer cell itself. Our findings identify a major mechanism through which MIF promotes cell survival and suppresses apoptosis that could be the basis for MIF's protumorigenic effects.
MIF has been shown to enhance proliferation and inhibit apoptosis of various cell types. These effects have been attributed in part to MIF-dependent activation of sustained MAPK signaling. This effect may lead to inhibition of p53 by MIF requiring serial activation of ERK1/2, cPLA2, cyclooxygenase 2 (COX2) and prostaglandin E2 (PGE2) (Mitchell et al., 1999) . MIF has been shown to antagonize p53-dependent gene expression (Hudson et al., 1999) . However, prolonged incubation of cells with MIF leads to downregulation of ERK signaling and a link between rapid MIF-mediated ERK signaling and p53 apoptosis has not been established (Lue et al., 2006) . Thus, although MIF-induced ERK signaling somewhat contributes to MIF's antiapoptotic properties, we reasoned that other, potentially more direct, mechanisms must exist. In particular, the initial molecular events triggering MIF-mediated apoptosis inhibition, which could lead to a subsequent downstream inhibition of p53 pathways by MIF, are unknown.
We speculated that MIF might act rapidly and directly on the Akt signaling pathway via a PI3K-dependent route. Activation of Akt by MIF could fully explain MIF's potent antiapoptotic effects and would be in accordance with MIF's cytokine/growth factor-like activity profile in inflammation and cancer (Calandra and Roger, 2003; Mitchell, 2004) . In fact, we demonstrated that MIF promoted PI3K/Akt signaling in primary MEFs, immortalized MEFs, fibroblasts and fibroblast-like cell lines. Importantly, MIF was also shown to promote Akt signaling in the p53-null cervix carcinoma line HeLa and in the p53-null breast cancer cell line MDA-MB-468. This function was linked to a significant MIF-mediated prosurvival effect following apoptotic stimulation by DNA damage or Fas. Enhancement of cell survival by MIF through PI3K/Akt is in line with observations by Amin et al. (2003 Amin et al. ( , 2005 , suggesting a role for PI3K in MIF-dependent endothelial cell migration and angiogenesis. Although these authors found that ERK1/2 and PI3K were essential for MIF's migratory effect on endothelial cells, Src, PI3K and NF-kB, but not ERK1/2, were involved in adhesion molecule upregulation. Thus, PI3K involvement was a common determinant in both angiogenesis-related settings.
Although participating in the regulation of cell motility, cytoskeletal rearrangement and glucose metabolism, the PI3K/Akt pathway is best known for controlling survival through functional modulation of various gene products (Shiojima and Walsh, 2002; Song et al., 2005) . We show that MIF activates PI3K and Src, and that this is linked to activation of the Akt pathway and enhancement of cell survival by MIF.
CD74 functions as a cell surface binding site for MIF. CD74 does not have a typical signal-transducing cytosolic domain, but the signal transducing coreceptor/pathway acting in conjunction with CD74 is just emerging in encompassing CD44 and a Src-type protein kinase (Leng et al., 2003; Shi et al., 2006) . Here, we have identified CD74, Src and PI3K as the upstream signaling cascade components necessary to mediate MIF-induced Akt activation.
Tumor cell proliferation is often characterized by autocrine effects of tumor cell-derived growth factors, acting as endogenous survival factors (Byrne et al., 2005) . We show that MIF can not only promote Akt signaling on a de novo basis by rapid stimulation, but also by autocrine action.
Of note, the intracellular MIF-binding protein, JAB1, was found to serve as a 'molecular sink' to prevent the secretion of MIF. JAB1 is part of the CSN, which is located in the nucleus and cytoplasm, where it can interact with MIF (Kleemann et al., 2000; Chamovitz and Segal, 2001; Bech-Otschir et al., 2002) . MIF is secreted from immune cells and fibroblasts by a nonconventional export pathway bypassing the ER/Golgi apparatus (Flieger et al., 2003; Nickel, 2003) . Upon protein synthesis, MIF is 'stored' in the cytosol before translocation into a secretion competent, yet unidentified, vesicular compartment (Bernhagen et al., 1993; Flieger et al., 2003) . This latter process is dependent on an ABCA1 transporter (Flieger et al., 2003) , and our current study demonstrates that JAB1 can retain MIF in the cytosol. JAB1 regulates cellular signaling such as the AP-1 and MAPK pathways (Chamovitz and Segal, 2001; Bech-Otschir et al., 2002; Lue et al., 2006) . JAB1 is overexpressed in many tumor entities and has been indirectly linked to prosurvival effects in several carcinomas, that is via p27 (Tomoda et al., 1999; Chamovitz and Segal, 2001; Adler et al., 2006; Osoegawa et al., 2006) , but does not directly regulate PI3K/Akt signaling. In line with findings, suggesting a JAB1/c-Myc-based mechanism underlying JAB1's role in breast cancer development, we have found no obvious correlation between JAB1 levels in several breast cancer cell lines and their Akt activation status. However, we have identified a novel-indirect-mechanism through which JAB1 imparts on the Akt pathway, that is by inhibiting MIF secretion and its autocrine prosurvival activities. Knock down of JAB1 by RNA interference led to a marked increase in secreted MIF in HEK293 cells. As expected, the cytosolic concentration of MIF protein, which is high in HEK cells and other cells at baseline, was only marginally affected by JAB1 knock down, confirming that MIF secretion is predominantly regulated at the secretion level (Flieger et al., 2003; Nickel, 2003) . Future studies will need to assess which vesicular proteins and pathways are involved in MIF secretion downstream of the JAB1-mediated retainment mechanism and whether the dramatic JAB1 effect on MIF secretion also occurs in tumor cells. Functionally it thus appears that the actions of the tumor-associated proteins MIF and JAB1 are coordinated by an interdependent 'fine-tuning' to prevent an excessive prosurvival response of the cell.
We could show that MIF-induced Akt activation leads to the phosphorylation and inactivation of two key proapoptotic proteins, namely BAD and Foxo3a. Most importantly, MIF-induced Akt phosphorylation was directly linked to the prosurvival effect of MIF in fibroblasts, HeLa cervix carcinoma cells, as well as PTEN-and p53-null breast cancer cells following apoptotic stimulation. Akt controls survival by phosphorylation of several substrate proteins. Phosphorylation of BAD and caspase-9 leads to the direct inactivation of these proapoptotic proteins, resulting in an immediate upregulation of survival. Indirect enhancement of survival by Akt is achieved through phosphorylation of key transcription factors. Phosphorylated IkB kinase complex promotes IkB degradation and NF-kB activation, resulting in enhanced transcription of NFkB-dependent survival genes such as Bcl-xL. Akt also phosphorylates and activates the E3 ligase Mdm2, resulting in p53 degradation and inhibition of p53-dependent gene transcription. Our data in HeLa cells and MDA-MB-468 breast cancer cells, which do not express functional p53, clearly indicate that MIFmediated Akt activation and apoptosis inhibition can occur independently of p53. As PTEN expression is under p53-dependent transcriptional control, our apoptosis results in the ZR-75-1 breast cancer cells, which have been reported to express both wild-type and mutant p53 (Zapata et al., 1998) , further confirm this notion. Survival of these cells following apoptotic challenge is at least partially dependent on autocrine MIF activity.
Foxo transcription factors including Foxo3a are inactivated by Akt-specific phosphorylation. This abolishes the Foxo-driven expression of proapoptotic genes such as Fas ligand or Bim, constituting another indirect way of survival control by Akt (Song et al., 2005) . In analysing the effect of MIF on Akt-mediated BAD and Foxo3a phosphorylation, we have addressed both the direct and indirect routes by which Akt controls cell survival.
In support of this notion, we were able to link directly MIF-mediated Akt phosphorylation with enhanced cell survival under various conditions in both normal fibroblasts and several cancer cell lines. When cell death was induced by the topoisomerase poison camptothecin, leading to irreversible DNA double-strand breaks, rMIF-treated fibroblasts were significantly protected from the ensuing apoptotic process observed 4-8 h later. This prosurvival effect of MIF, as described for various growth factors, correlated with a transient phospho-Akt signal at 20 min (Cheng et al., 2005) . That MIF can protect cells from DNA damage-induced death in an Akt-dependent manner was further confirmed in several breast cancer cell lines (see below) and in fibroblasts challenged with the ROS-inducing agent tBHP, mimicking endogenous oxygen stress-induced apoptosis and thus (patho)physiological stress conditions that are assumed to contribute to the transformation of chronic inflammatory stimulation into tumor development.
Notably, MIF provided a prosurvival signal upon overexpressing Fas receptor. Activation in the HeLa/ Tet-off cell model of the prototypical death pathway by Fas receptor cross-linking led to a marked elevation of phospho-Akt levels by autocrine MIF action, peaking 60-240 min post-challenge. This correlated well with the prosurvival effect triggered by MIF in that cellular system, which manifested between 60 min and 18 h. Given that we identified BAD and Foxo3a as MIFinduced Akt substrates, we propose that MIF-mediated elevated survival in the NIH/3T3/camptothecin and MEF/tBHP systems is due to a derepression of the BAD-Bcl-2/Bcl-xL interaction and the various effects of Bcl-2 on the DNA damage-induced apoptotic pathways, foremostly the mitochondrial pathway. As discussed, in the HeLa/Fas system, MIF acts fully independently of the p53 pathway. In this system, MIF-mediated protection might be due to promoting an Akt-dependent inhibitory effect of Bcl-2 on caspase-3 activation. Importantly, our PTEN knock down and overexpression data implying that MIF does not exert prosurvival effects independently of the PI3K/Akt axis, corroborate this notion. Induction of the autocrine MIF pathway exhibited a prosurvival effect that was similar to that observed after PTEN knock down, whereas MIF induction did not elevate the survival rate any further. We assume that failure of MIF to improve further survival under these conditions is due to the fact that the Akt pathway is already maximally activated, when PTEN is functionally inactivated. When survival of the HeLa cervix carcinoma cells was minimal owing to PTEN overexpression, MIF also was unable to increase survival, most likely because signaling through the PI3K/Akt pathway is essentially blocked under such conditions.
A causal relationship between MIF-mediated Akt signaling, the PTEN status of a cell and survival was finally confirmed by studying phospho-Akt levels and survival of several breast cancer cell lines, featuring different PTEN phenotypes and endogenous MIF expression levels. At the same time, this system constituted a relevant cancer cell model, as MIF is strongly overexpressed in breast cancer and has been suggested to be associated with breast cancer development (Bando et al., 2002; Hagemann et al., 2005) . Our results indicate that enhancement by MIF of Akt phosphorylation and survival is most marked in PTENand p53-negative breast cancer cells, whereas PTEN-and p53-positive breast cancer cells are unresponsive to exogenous MIF with respect to Akt activation and only seem to depend on MIF regarding their survival to a minor extent. Thus, interfering with the Akt pathway by increasing the levels of the Akt inhibitor PTEN in cancer cells by artificial overexpression or natural phenotype, ablates the antiapoptotic effects of MIF that are otherwise observed to contribute significantly to the survival of these cells. We therefore speculate that MIF may be critical for tumor cell survival and expansion especially in situations where the tumors express low or no PTEN. Moreover, the PTEN-siRNA results in HeLa could indicate that, depending on other survival factors, MIF's prosurvival role may be most critical for a tumor cell, when the PI3K/Akt pathway is submaximally activated. Interestingly, it has been suggested that MIF may be particularly important in breast cancers with minimal nodal spread or with a node-negative phenotype and that MIF might play a role in tumor-stroma interactions of primary breast cancers (Bando et al., 2002) . In support of such a notion, Hagemann et al. (2005) have additionally implicated MIF in macrophageinduced invasiveness of epithelial breast cancer cells . These findings certainly justify future exploration in the context of our current results, bearing in mind, that the activation/blockade by MIF of other, Akt-independent apoptosis/survival-regulating pathways cannot be fully ruled out at the present time.
In conclusion, our findings imply that the recently uncovered protumorigenic activities of MIF are at least partly owing to an upregulation of PI3K/Akt signaling and cell survival by MIF. Given MIF's critical role as an inflammatory mediator, our results moreover support the contention that MIF constitutes an important molecular link between inflammation and cancer.
Materials and methods
Reagents JAB1-siRNA oligonucleotides were from MWG Biotech (Ebersberg, Germany). Lipofectamin 2000 was from Invitrogen (Karlsruhe, Germany). Protease inhibitor cocktail, Ly294002, wortmannin, genistein and PP2 were from Merck-Biosciences/ Calbiochem (Darmstadt, Germany). The IC 50 values for these inhibitors and applied concentrations were as follows: Ly294002, IC 50 ¼ 1.4 mM, applied ¼ 1, 5 and 25 mM as indicated; wortmannin, IC 50 ¼ 5 nM, applied ¼ 100 nM; genistein, IC 50 ¼ 2.6 mM, applied ¼ 25 mM; PP2, IC 50 ¼ 4-5 nM, applied ¼ 100 nM. Thus, unless indicated otherwise, inhibitors were used at concentrations 10-20-fold above the corresponding IC 50 values.
Anti-phospho-Akt (Ser473), anti-phospho-BAD (Ser136), anti-Bad and antiphospho-Foxo3a (Ser253) were from Cell Signaling Technology (Danvers, MA, USA). For anti-phospho-GSK-3b see below. Anti-JAB1/CSN5 (FL-334), antiAkt, anti-Src (N-16), anti-actin (H-196), anti-phospho-ERK1/2 (E-4) and anti-ERK1/2 (C-16) were from Santa Cruz Biotechnoogy (Heidelberg, Germany). Sheep anti-mouse (Fab 0 ) 2 and donkey anti-rabbit Ig, conjugated with peroxidase, were from Amersham Biosciences (Munich, Germany). Neutralizing MIF mAb (IIID.9) and isotype IgG were prepared as described (Schober et al., 2004) and were used at a 100-fold molar excess.
Recombinant human MIF (rMIF) was prepared from pET11b/BL21-DE3 as described (Kleemann et al., 2000) . rMIF contained o5 pg lipopolysaccharide/mg rMIF as determined by (Limulus QCL-1000; (Cambrex BioScience, Verviers, Belgium).
Cell culture
Cell culture reagents were from Invitrogen. MIF À/À and wtMEFs were from the Bucala/Fingerle labs and were prepared as described (Fingerle-Rowson et al., 2003) . MEFs were cultured in Dulbecco's modified Eagle medium (DMEM), containing 10% fetal calf serum (FCS). Primary MEFs were used at passage 3-5 and large T-antigen-immortalized MEFs at passage 10-20.
NIH/3T3 fibroblasts, HEK293 cells and Src-/Yes-/Fyndeficient (SYF À/À )MEFs derived from Src-triple knock out SYF mice and SYF À/À MEFs re-expressing wtSrc (SYF À/À þ Src cells) were maintained as described (Lue et al., 2006) . Src levels were determined in these three cell types to confirm Src-type kinase knock down and re-expression by Src Western blot in relation to actin. CD74 À/À MEFs have been described (Leng et al., 2003) . For restoration of CD74 expression in CD74 À/ À MEFs, these MEFs were transfected with 3.3 mg pcDNA-CD74 (Leng et al., 2003) using the Amaxa transfection system (Amaxa GmbH, Cologne, Germany). The Amaxa MEF-2 kit in combination with protocol #A-23 was used according to the manufacturer's instructions. pGFP was used to control for transfection efficiency at a 1/10 ratio, and an efficiency of 40-45% was reached. Transfected CD74 À/À MEFs were incubated for 48 h to allow for CD74 overexpression before Akt stimulations were started. HeLa/HtTA8/8 cells stably expressing MIF under control of a Tet-off cassette were cultured and induced as described (Nguyen et al., 2003) . The normal mammary epithelial cell line MCF-12A and the breast carcinoma cell lines MCF-7 (infiltrating ductal adenocarcinoma), MDA-MB-468 (infiltrating adenocarcinoma) and ZR-75-1 (infiltrating ductal carcinoma) were obtained from the Dahl lab (source ATCC) and were cultured as described previously (Veeck et al., 2006) . Briefly, MCF-12A cells were cultured in MDEM medium containing 10% FCS and were additionally supplemented with 10 mg/ml insulin, 500 ng/ml hydrocortisone and 20 ng/ml epidermal growth factor (SigmaAldrich, Munich, Germany). MCF-7, MDA-MB-468 and ZR-75-1 cells were maintained in DMEM or RMPI 1640 medium containing 10% FCS.
PI3K/Akt activation, BAD phosphorylation and Western blotting Activation of PI3K/Akt by MIF and Western blot analysis with anti-phospho-ERK1/2, anti-phospho-Akt, anti-phospho-BAD, or anti-phospho-Foxo3a was performed essentially as described (Lue et al., 2006) . For standardization, loading was adjusted for equal cell equivalents, and membranes were reprobed for Akt, BAD, or actin. Expression of standard proteins did not change during the course of the experiments and blots were quantitated in relation to them ('phosphorylation ratio'). Quantifications are representative of two-eight independent experiments (for details see figure legends). For phospho-BAD analyses, NIH/3T3 cells were transfected with pEBG-mBad (Cell Signaling) using ExGen500 (Fermentas, St Leon-Rot, Germany). After 24 h, medium was exchanged for DMEM/ 0.5% FCS and cells were starved for 24 h before treatment with rMIF for 20 min and phospho-BAD/total BAD analysis. Band densitometry was performed by the Aida Image Analyzer (Raytest Isotopenmessgerat GmbH) and J-Image Software.
In vitro Akt kinase assay Activation of Akt was determined by in vitro Akt kinase Kit using GSK-3b fusion protein according to the manufacturer's instructions (Cell Signaling). Quantifications were performed by densitometry of the phospho-GSK-3/Akt ratios ('relative Akt activity') and are representative of at least three independent experiments. JAB1/CSN5 knock down and MIF ELISA JAB1/CSN5 levels were knocked down by siRNA for 72-96 h as described (Lue et al., 2006) . Western blots for P-Akt, JAB1 were performed as above. To assess the cellular/cytosolic MIF levels in these cells, MIF was measured by Western blot from cell lysates using the rabbit polyclonal antibody Ka565 as described (Kleemann et al., 2000) . Analysis of MIF secretion in the siRNA-versus scrambled RNA-treated HEK293 supernatants was performed by commercial MIF ELISA (R&D Systems, Wiesbaden, Germany).
Apoptosis/survival assays Fibroblast survival was assessed following apoptosis induction by camptothecin (NIH/3T3) or tBHP (primary MEFs). NIH/ 3T3 fibroblasts were treated with 1 mg/ml camptothecin with or without 50 ng/ml rMIF. Apoptosis was determined after 0-8 h counting Annexin-V-positive cells by fluorescence microscopy. In parallel, cell death was evaluated by counting propidium iodide-positive cells. Apoptosis in MEFs was analysed by comparing wtMEFs with MIF À/À MEFs upon treatment with 250 mM tBHP, which induces ROS-mediated cell death. Apoptosis was evaluated by nuclear staining and counting of cells with typical apoptotic morphology.
For apoptosis studies in the HeLa/Fas system, Tet-responsive HeLa cervix carcinoma cells were cultured in 24-well plates with or without 1 mg/ml doxycyclin, and cotransfected with 0.1 mg/well Fas receptor plasmid pCR3-FasR (kindly provided by Dr Tschopp, Switzerland) with the Fugene 6 transfection reagent (Roche Diagnostics, Mannheim, Germany) to sensitize cells to agonistic Fas antibody. For selection of transfected cells, cells were cotransfected with 0.1 mg/well EGFP plasmid ('counting of green cells') or pBABE-puro ('selection for antibiotic resistance'). In the latter case, cells were selected for another 24 h with 5 mg/ml puromycin, cultured for 24 h in normal medium, before apoptosis was induced by addition of Fas antibody (1:8000 dilution; CH11, Biomol, Hamburg, Germany) for the indicated time intervals. Apoptosis was determined by counting EGFP-positive and/or puromycinresistant cells with a typical apoptotic morphology following nuclear staining (Hoechst 33342) and fluorescent microscopic analysis. For silencing or overexpression of PTEN, the pSUPER-siPTEN plasmid (RNAi sequence: 5 0 -GTCA-GAGGCGCTATGTGTA-3 0 ) or a PTEN overexpression vector (pcDNA-PTEN) was cotransfected with pCR3-Fas at 0.1 mg/well. For control, the pSUPER vector carrying an unrelated sequence (5 0 -CCCTGCAGATCCATGCTT-3 0 ) was applied.
Apoptosis studies in the breast cancer cells were performed as follows: cells were pretreated for 30 min with either 0, 1 or 5 mM Ly294002 to block PI3K/Akt signaling or with the neutralizing MIF mAb IIID.9 to inhibit autocrine MIF activity. This was followed by an incubation with 100 mM etoposide for 10-24 h depending on the cell line, to reach an apoptotic degree of approximately 10% in the etoposidetreated control cells. Apoptotic cells were determined by Annexin-V-positive staining using the Annexin-V-FLUOS Staining Kit (Roche Diagnostics) and fluorescence microscopy. In parallel, cell death analysis was also performed by counting propidium iodide-positive cells according to the manufacturer's instructions.
